(VIANEWS) – Monroe Capital Corporation (MRCC), Sabra Health Care REIT (SBRA), Nuveen Massachusetts Premium Income Municipal Fund (NMT) have the highest dividend yield stocks on this list.
| Financial Asset | Forward Dividend Yield | Updated (EST) |
|---|---|---|
| Monroe Capital Corporation (MRCC) | 13.32% | 2024-07-10 16:23:05 |
| Sabra Health Care REIT (SBRA) | 7.67% | 2024-07-11 22:43:06 |
| Nuveen Massachusetts Premium Income Municipal Fund (NMT) | 7.65% | 2024-07-04 23:47:06 |
| Nuveen Multi (JMM) | 5.47% | 2024-07-04 01:43:05 |
| Orrstown Financial Services (ORRF) | 2.96% | 2024-07-11 01:42:06 |
| Qiagen N.V. (QGEN) | 2.94% | 2024-07-11 13:23:07 |
Close to 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. Monroe Capital Corporation (MRCC) – Dividend Yield: 13.32%
Monroe Capital Corporation’s last close was $7.51, 15.14% under its 52-week high of $8.85. Intraday change was 1.2%.
Monroe Capital Corporation is a business development company specializing in customized financing solutions in senior, unitranche and junior secured debt and to a lesser extent, unsecured debt and equity, including equity co-investments in preferred and common stock and warrants. It also provides financing primarily to buyouts in lower middle-market companies. It focuses to invest in the United States and Canada. The fund prefers to invest in companies with EBITDA between $3 and $35 million.
Earnings Per Share
As for profitability, Monroe Capital Corporation has a trailing twelve months EPS of $0.01.
PE Ratio
Monroe Capital Corporation has a trailing twelve months price to earnings ratio of 760. Meaning, the purchaser of the share is investing $760 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.1%.
Volume
Today’s last reported volume for Monroe Capital Corporation is 38819 which is 40.38% below its average volume of 65114.
More news about Monroe Capital Corporation.
2. Sabra Health Care REIT (SBRA) – Dividend Yield: 7.67%
Sabra Health Care REIT’s last close was $15.64, 0.89% below its 52-week high of $15.78. Intraday change was 2.16%.
As of March 31, 2022, Sabra's investment portfolio included 416 real estate properties held for investment. This consists of (i) 279 Skilled Nursing/Transitional Care facilities, (ii) 59 Senior Housing communities (“Senior Housing – Leased”), (iii) 50 Senior Housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing – Managed”), (iv) 13 Behavioral Health facilities and (v) 15 Specialty Hospitals and Other facilities), one asset held for sale, one investment in a sales-type lease, 16 investments in loans receivable (consisting of (i) two mortgage loans, (ii) one construction loan and (iii) 13 other loans), seven preferred equity investments and one investment in an unconsolidated joint venture. As of March 31, 2022, Sabra's real estate properties held for investment included 41,445 beds/units, spread across the United States and Canada.
Earnings Per Share
As for profitability, Sabra Health Care REIT has a trailing twelve months EPS of $0.21.
PE Ratio
Sabra Health Care REIT has a trailing twelve months price to earnings ratio of 74.48. Meaning, the purchaser of the share is investing $74.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.72%.
Yearly Top and Bottom Value
Sabra Health Care REIT’s stock is valued at $15.64 at 10:15 EST, under its 52-week high of $15.78 and way higher than its 52-week low of $11.73.
Volume
Today’s last reported volume for Sabra Health Care REIT is 2398600 which is 30.69% above its average volume of 1835250.
Volatility
Sabra Health Care REIT’s last week, last month’s, and last quarter’s current intraday variation average was 1.61%, 0.54%, and 1.01%.
Sabra Health Care REIT’s highest amplitude of average volatility was 1.61% (last week), 0.91% (last month), and 1.01% (last quarter).
More news about Sabra Health Care REIT.
3. Nuveen Massachusetts Premium Income Municipal Fund (NMT) – Dividend Yield: 7.65%
Nuveen Massachusetts Premium Income Municipal Fund’s last close was $11.13, 0.98% below its 52-week high of $11.24. Intraday change was 0.09%.
Nuveen Massachusetts Quality Municipal Income Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of Massachusetts, United States. The fund primarily invests in undervalued municipal securities and other related investments which are exempt from regular federal and Massachusetts income taxes. It seeks to invest in investment grade securities that are rated Baa/BBB or above by S&P, Moody's, or Fitch. The fund employs fundamental analysis with a focus on bottom-up stock picking approach to create its portfolio. It benchmarks the performance of its portfolio against the Standard & Poor's (S&P) Massachusetts Municipal Bond Index and Standard & Poor's (S&P) National Municipal Bond Index. The fund was formerly known as Nuveen Massachusetts Premium Income Municipal Fund. Nuveen Massachusetts Quality Municipal Income Fund was formed on January 12, 1993 and is domiciled in the United States.
Earnings Per Share
As for profitability, Nuveen Massachusetts Premium Income Municipal Fund has a trailing twelve months EPS of $0.29.
PE Ratio
Nuveen Massachusetts Premium Income Municipal Fund has a trailing twelve months price to earnings ratio of 38.38. Meaning, the purchaser of the share is investing $38.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.46%.
More news about Nuveen Massachusetts Premium Income Municipal Fund.
4. Nuveen Multi (JMM) – Dividend Yield: 5.47%
Nuveen Multi’s last close was $6.03, 1.47% under its 52-week high of $6.12. Intraday change was 1.69%.
Nuveen Multi-Market Income Fund is a closed-ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of the United States. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in investment grade debt securities such as U.S. agency and privately issued mortgage-backed securities, corporate debt securities, and asset-backed securities. The fund was formerly known as American Income Fund, Inc. Nuveen Multi-Market Income Fund was formed on December 30, 1988 and is domiciled in the United States.
Earnings Per Share
As for profitability, Nuveen Multi has a trailing twelve months EPS of $0.48.
PE Ratio
Nuveen Multi has a trailing twelve months price to earnings ratio of 12.56. Meaning, the purchaser of the share is investing $12.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.83%.
More news about Nuveen Multi.
5. Orrstown Financial Services (ORRF) – Dividend Yield: 2.96%
Orrstown Financial Services’s last close was $27.06, 9.16% below its 52-week high of $29.79. Intraday change was 0.45%.
Orrstown Financial Services, Inc. operates as the holding company for Orrstown Bank that provides commercial banking and trust services in the United States. The company accepts various deposits, including checking, savings, time, demand, and money market deposits. It also offers commercial loans, such as commercial real estate, equipment, construction, working capital, and other commercial purpose loans, as well as industrial loans; consumer loans comprising home equity and other consumer loans, as well as home equity lines of credit; residential mortgage loans; acquisition and development loans; municipal loans; and installment and other loans. In addition, the company provides renders services as trustee, executor, administrator, guardian, managing agent, custodian, and investment advisor, as well as provides other fiduciary services under the Orrstown Financial Advisors name; and offers retail brokerage services through a third-party broker/dealer arrangement. Further, it offers investment advisory, insurance, and brokerage services. The company operates through offices in Berks, Cumberland, Dauphin, Franklin, Lancaster, Perry, and York counties, Pennsylvania; and Anne Arundel, Baltimore, Howard, and Washington counties, Maryland, as well as Baltimore City, Maryland. Orrstown Financial Services, Inc. was founded in 1919 and is based in Shippensburg, Pennsylvania.
Earnings Per Share
As for profitability, Orrstown Financial Services has a trailing twelve months EPS of $3.36.
PE Ratio
Orrstown Financial Services has a trailing twelve months price to earnings ratio of 8.05. Meaning, the purchaser of the share is investing $8.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.69%.
Volume
Today’s last reported volume for Orrstown Financial Services is 97493 which is 0.44% below its average volume of 97924.
More news about Orrstown Financial Services.
6. Qiagen N.V. (QGEN) – Dividend Yield: 2.94%
Qiagen N.V.’s last close was $41.03, 13.98% below its 52-week high of $47.70. Intraday change was 0.68%.
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Earnings Per Share
As for profitability, Qiagen N.V. has a trailing twelve months EPS of $1.52.
PE Ratio
Qiagen N.V. has a trailing twelve months price to earnings ratio of 27.18. Meaning, the purchaser of the share is investing $27.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.41%.
Sales Growth
Qiagen N.V.’s sales growth is 0.4% for the present quarter and 5.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.5%, now sitting on 1.94B for the twelve trailing months.
Yearly Top and Bottom Value
Qiagen N.V.’s stock is valued at $41.31 at 10:15 EST, way under its 52-week high of $47.70 and way above its 52-week low of $34.74.
Moving Average
Qiagen N.V.’s worth is below its 50-day moving average of $43.01 and under its 200-day moving average of $42.06.
More news about Qiagen N.V..
